Victory Joseph Selected Research

GDC-0334

1/2021	Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
1/2021	A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Victory Joseph Research Topics

Disease

2	Pain (Aches) 01/2021 - 01/2021
2	Retinal Degeneration 01/2016 - 11/2012
1	Inflammation (Inflammations) 01/2021
1	Asthma (Bronchial Asthma) 01/2021
1	Edema (Dropsy) 01/2021
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2021
1	Cough 01/2021
1	Epstein-Barr Virus Infections 10/2016
1	Retinitis Pigmentosa (Pigmentary Retinopathy) 11/2012

Drug/Important Bio-Agent (IBA)

2	GDC-0334IBA 01/2021 - 01/2021
2	Transient Receptor Potential ChannelsIBA 01/2021 - 01/2021
2	Rhodopsin (Visual Purple)IBA 01/2016 - 11/2012
1	2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate (AITC)IBA 01/2021
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2016
1	LigandsIBA 10/2016
1	Proteins (Proteins, Gene)FDA Link 11/2012
1	Immunoglobulins (Immunoglobulin)IBA 11/2012
1	CCAAT-Enhancer-Binding ProteinsIBA 11/2012

Therapy/Procedure

1	Therapeutics 01/2021